Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Immunicum AB Completes Treatment of Last Patient in Its Kidney Cancer Vaccine Phase I/II-Study


Monday, 19 Aug 2013 04:05am EDT 

Immunicum AB announced that the last scheduled patient in the Company's phase I/II study in metastatic renal cancer received the concluding dose of the cancer vaccine INTUVAX. The study is conducted at the University Hospital in Uppsala and at Norrland University Hospital. A total of 12 patients with metastatic renal cancer have been treated with the cancer vaccine INTUVAX and the results have so far shown promise. On May 20, Immunicum reported a status update where the Company concluded that no serious vaccine-related adverse events have been recorded and that the immune system appears to be activated specifically against cancer. In addition, immunological findings suggest that the immune system also has an effect on metastases and not only in the primary tumor where the vaccine was administered. No patients have yet passed away and survival data for patients with poor prognosis already looks promising. Two patients in this subgroup have thus far shown an average survival of about 14 months, which may be compared to the expected median survival of 5 months for untreated patients and about 8 months for patients treated with existing therapies, such as Sutent, that are also associated with adverse effects. In parallel with the completion of the phase I/II-study in renal cancer, Immunicum will intensify its work in the fall with planning the upcoming phase II-trial in renal cancer and focus on the initiation of the Company‚Äôs newly approved phase I/II-trial in liver cancer.